Human Reproduction, Vol. 14, No. 8, 1956-1959,
August 1999
© 1999 European Society of Human Reproduction and Embryology
Human reproductive failure is not a clinical feature associated with ß2 glycoprotein-I antibodies in anticardiolipin and lupus anticoagulant seronegative patients (the antiphospholipid/cofactor syndrome)
1 Institut Clínic of Gynecology, Obstetrics and Neonatology, 2 Hemotherapy and Hemostasis Unit and 3 Unit of Systemic Autoimmune Diseases, Faculty of Medicine, University of Barcelona, Barcelona, Spain
It has been suggested that patients with clinical features suggestive of antiphospholipid syndrome but being lupus anticoagulant (LA) and anticardiolipin (aCL) negative, should be tested for antibodies to ß2 glycoprotein-I (aß2GP-I), a protein involved in the binding of antiphospholipid antibodies (aPL) to phospholipid surfaces. This was investigated in the present study where a total of 385 women aged 
40 years were included. Of these, 175 were experimental subjects and 210 were controls. The former comprised the following two study groups: 100 spontaneous recurrent aborters (group one), and 75 patients with repeated failure of embryo transfer (group two). Controls included three groups of women: 100 normal healthy parous women with no previous abortion (group three), 60 infertile patients achieving a live birth with their first in-vitro fertilization (IVF)/embryo transfer attempt (group four), and 50 patients with recurrent abortion who tested positive for aPL (LA and/or aCL) (positive controls, group five). Only one patient among recurrent aborters (group one) tested positive for aß2GP-I. All women in groups two, three and four were negative for aß2GP-I screening. As expected, prevalence of patients testing positive for aß2GP-I was significantly higher in group five than among the other groups of patients (P < 0.001). No differences were observed regarding the prevalence of aß2GP-I positive sera in the subgroup of patients having aCL and those having the LA in group five. It is concluded that aß2GP-I screening in first-trimester recurrent abortion or in failure of implantation after IVF is not warranted in patients without aPL as detected by standard antiphospholipid assays.
Key words: antiphospholipid antibodies/ß2 glycoprotein-I/implantation failure/IVF/recurrent abortion
4 To whom correspondence should be addressed at: Institut Clínic of Gynecology, Obstetrics and Neonatology, Hospital Clínic,C/Casanova 143, 08036-Barcelona, Spain
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. P. Audrain, D. El Kouri, M. A. Hamidou, L. Mioche, A. Ibara, M.-L. Langlois, and J.-Y. Muller Value of autoantibodies to {beta}2-glycoprotein 1 in the diagnosis of antiphospholipid syndrome Rheumatology, May 1, 2002; 41(5): 550 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stern, H.W.G. Baker, L. Chamley, J. Balasch, and J. C. Reverter Human reproductive failure is not a clinical feature associated with {beta}2 glycoprotein-I antibodies in anticardiolipin and lupus anticoagulant seronegative patients Hum. Reprod., April 1, 2000; 15(4): 976 - 978. [Full Text] [PDF]
|
|